Advanced search
Publication Cover
Expert Review of Dermatology Volume 8, 2013 - Issue 1
Journal homepage
6
Views
0
CrossRef citations to date
0
Altmetric
Review

Cutaneous and systemic Lyme disease

Jenny Deluca Department of Dermatology, Central Teaching Hospital of Bolzano, L. Böhlerstr. 5, 39100 Bolzano/Bozen, Italy. [email protected]; Department of Dermatology, Central Teaching Hospital of Bolzano, L. Böhlerstr. 5, 39100 Bolzano/Bozen, Italy. [email protected]
,
Klaus Eisendle Department of Dermatology, Central Teaching Hospital of Bolzano, L. Böhlerstr. 5, 39100 Bolzano/Bozen, Italy. [email protected]; Department of Dermatology, Central Teaching Hospital of Bolzano, L. Böhlerstr. 5, 39100 Bolzano/Bozen, Italy. [email protected]
&
Bernhard Zelger Department of Dermatology, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria; Department of Dermatology, Medical University Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria
Pages 65-82 | Published online: 10 Jan 2014

References

  • Southwick F. Zoonotic infections. In: Infectious Disease: A Clinical Short Course. MacGraw Hill, NY, USA, 322–328 (2007).
  • Strle F. Principles of the diagnosis and antibiotic treatment of Lyme borreliosis. Wien. Klin. Wochenschr. 111(22–23), 911–915 (1999).
  • Stanek G, Reiter M. The expanding Lyme Borrelia complex–clinical significance of genomic species? Clin. Microbiol. Infect. 17(4), 487–493 (2011).
  • Rauter C, Hartung T. Prevalence of Borrelia burgdorferi sensu lato genospecies in Ixodes ricinus ticks in Europe: a metaanalysis. Appl. Environ. Microbiol. 71(11), 7203–7216 (2005).
  • Steere AC. Lyme disease. N. Engl. J. Med. 345(2), 115–125 (2001).
  • Wilske B, Fingerle V, Schulte-Spechtel U. Microbiological and serological diagnosis of Lyme borreliosis. FEMS Immunol. Med. Microbiol. 49(1), 13–21 (2007).
  • Fraser CM, Casjens S, Huang WM et al. Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi. Nature 390(6660), 580–586 (1997).
  • Estrada-Peña A, Ortega C, Sánchez N et al. Correlation of Borrelia burgdorferi sensu lato prevalence in questing Ixodes ricinus ticks with specific abiotic traits in the western palearctic. Appl. Environ. Microbiol. 77(11), 3838–3845 (2011).
  • Rizzoli A, Hauffe H, Carpi G, Vourc H G, Neteler M, Rosa R. Lyme borreliosis in Europe. Euro Surveill. 16(27), (2011).
  • Tsao JI. Reviewing molecular adaptations of Lyme borreliosis spirochetes in the context of reproductive fitness in natural transmission cycles. Vet. Res. 40(2), 36 (2009).
  • Schwan TG, Piesman J, Golde WT, Dolan MC, Rosa PA. Induction of an outer surface protein on Borrelia burgdorferi during tick feeding. Proc. Natl Acad. Sci. USA 92(7), 2909–2913 (1995).
  • de Silva AM, Fikrig E. Arthropod- and host-specific gene expression by Borrelia burgdorferi. J. Clin. Invest. 99(3), 377–379 (1997).
  • Heyman P, Cochez C, Hofhuis A et al. A clear and present danger: tick-borne diseases in Europe. Expert Rev. Anti. Infect. Ther. 8(1), 33–50 (2010).
  • Stanek G, Wormser GP, Gray J, Strle F. Lyme borreliosis. Lancet 379(9814), 461–473 (2012).
  • Rosa P. Lyme disease agent borrows a practical coat. Nat. Med. 11(8), 831–832 (2005).
  • Wormser GP, Brisson D, Liveris D et al. Borrelia burgdorferi genotype predicts the capacity for hematogenous dissemination during early Lyme disease. J. Infect. Dis. 198(9), 1358–1364 (2008).
  • Nadelman RB, Nowakowski J, Forseter G et al. The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans. Am. J. Med. 100(5), 502–508 (1996).
  • Schutzer SE, Janniger CK, Schwartz RA. Lyme disease during pregnancy. Cutis. 47(4), 267–268 (1991).
  • Kirkland KB, Klimko TB, Meriwether RA et al. Erythema migrans-like rash illness at a camp in North Carolina: a new tick-borne disease? Arch. Intern. Med. 157(22), 2635–2641 (1997).
  • Wormser GP, Masters E, Liveris D et al. Microbiologic evaluation of patients from Missouri with erythema migrans. Clin. Infect. Dis. 40(3), 423–428 (2005).
  • Feder HM Jr, Johnson BJ, O’Connell S et al.; Ad Hoc International Lyme Disease Group. A critical appraisal of ‘chronic Lyme disease’. N. Engl. J. Med. 357(14), 1422–1430 (2007).
  • Philipp MT, Masters E, Wormser GP, Hogrefe W, Martin D. Serologic evaluation of patients from Missouri with erythema migrans-like skin lesions with the C6 Lyme test. Clin. Vaccine Immunol. 13(10), 1170–1171 (2006).
  • Barbour AG, Maupin GO, Teltow GJ, Carter CJ, Piesman J. Identification of an uncultivable Borrelia species in the hard tick Amblyomma americanum: possible agent of a Lyme disease-like illness. J. Infect. Dis. 173(2), 403–409 (1996).
  • Varela AS, Luttrell MP, Howerth EW et al. First culture isolation of Borrelia lonestari, putative agent of southern tick-associated rash illness. J. Clin. Microbiol. 42(3), 1163–1169 (2004).
  • Masters E, Granter S, Duray P, Cordes P. Physician-diagnosed erythema migrans and erythema migrans-like rashes following Lone Star tick bites. Arch. Dermatol. 134(8), 955–960 (1998).
  • Oliveira Ad, Fonseca AH, Costa CM, Mantovani E, Yoshinari NH. Growth, cysts and kinetics of Borrelia garinii (Spirochaetales: Spirochaetacea) in different culture media. Mem. Inst. Oswaldo Cruz 105(5), 717–719 (2010).
  • Costa IP, Bonoldi VL, Yoshinari NH. Search for Borrelia sp. in ticks collected from potential reservoirs in an urban forest reserve in the State of Mato Grosso do Sul, Brazil: a short report. Mem. Inst. Oswaldo Cruz 97(5), 631–635 (2002).
  • Yoshinari NH, Mantovani E, Bonoldi VL, Marangoni RG, Gauditano G. [Brazilian Lyme-like disease or Baggio–Yoshinari syndrome: exotic and emerging Brazilian tick-borne zoonosis]. Rev. Assoc. Med. Bras. 56(3), 363–369 (2010).
  • Hofmann H. [Lyme borreliosis. Cutaneous manifestation]. Hautarzt. 56(8), 783–95; quiz 796 (2005).
  • Mullegger RR. Dermatological manifestations of Lyme borreliosis. Eur. J. Dermatol. 14(5), 296–309 (2004).
  • Chodynicka B, Flisiak I, Okrasinska K, Andrzejewska A, Schwartz RA. Lymphocytoma cutis: cases linked with Lyme disease. Cutis. 66(4), 243–246 (2000).
  • Maraspin V, Cimperman J, Lotric-Furlan S et al. Solitary borrelial lymphocytoma in adult patients. Wien. Klin. Wochenschr. 114(13–14), 515–523 (2002).
  • Pohl-Koppe A, Wilske B, Weiss M, Schmidt H. Borrelia lymphocytoma in childhood. Pediatr. Infect. Dis. J. 17(5), 423–426 (1998).
  • Bhate C, Schwartz RA. Lyme disease: part I. advances and perspectives. J. Am. Acad. Dermatol. 64(4), 619–36; quiz 637 (2011).
  • MacDonald AB. Human fetal borreliosis, toxemia of pregnancy, and fetal death. Zentralbl. Bakteriol. Mikrobiol. Hyg. A. 263(1–2), 189–200 (1986).
  • Markowitz LE, Steere AC, Benach JL, Slade JD, Broome CV. Lyme disease during pregnancy. JAMA 255(24), 3394–3396 (1986).
  • Schlesinger PA, Duray PH, Burke BA, Steere AC, Stillman MT. Maternal-fetal transmission of the Lyme disease spirochete, Borrelia burgdorferi. Ann. Intern. Med. 103(1), 67–68 (1985).
  • Maraspin V, Cimperman J, Lotric-Furlan S, Pleterski-Rigler D, Strle F. Erythema migrans in pregnancy. Wien. Klin. Wochenschr. 111(22–23), 933–940 (1999).
  • Lakos A, Solymosi N. Maternal Lyme borreliosis and pregnancy outcome. Int. J. Infect. Dis. 14(6), e494–e498 (2010).
  • Hercogova J, Vanousova D. Syphilis and borreliosis during pregnancy. Dermatol. Ther. 21(3), 205–209 (2008).
  • Kaya G, Berset M, Prins C, Chavaz P, Saurat JH. Chronic borreliosis presenting with morphea- and lichen sclerosus et atrophicus-like cutaneous lesions. A case report. Dermatology (Basel). 202(4), 373–375 (2001).
  • Eisendle K, Zelger B. The expanding spectrum of cutaneous borreliosis. G. Ital. Dermatol. Venereol. 144(2), 157–171 (2009).
  • Anthonissen FM, De Kesel M, Hoet PP, Bigaignon GH. Evidence for the involvement of different genospecies of Borrelia in the clinical outcome of Lyme disease in Belgium. Res. Microbiol. 145(4), 327–331 (1994).
  • Jelic S, Filipovic-Ljeskovic I. Positive serology for Lyme disease borrelias in primary cutaneous B-cell lymphoma: a study in 22 patients; is it a fortuitous finding? Hematol. Oncol. 17(3), 107–116 (1999).
  • Garbe C, Stein H, Gollnick H, Taud W, Orfanos CE. [Cutaneous B cell lymphoma in chronic Borrelia burgdorferi infection. Report of 2 cases and a review of the literature]. Hautarzt. 39(11), 717–726 (1988).
  • Garbe C, Stein H, Dienemann D, Orfanos CE. Borrelia burgdorferi-associated cutaneous B cell lymphoma: clinical and immunohistologic characterization of four cases. J. Am. Acad. Dermatol. 24(4), 584–590 (1991).
  • Goodlad JR, Davidson MM, Hollowood K et al. Primary cutaneous B-cell lymphoma and Borrelia burgdorferi infection in patients from the Highlands of Scotland. Am. J. Surg. Pathol. 24(9), 1279–1285 (2000).
  • Goodlad JR, Davidson MM, Hollowood K, Batstone P, Ho-Yen DO. Borrelia burgdorferi-associated cutaneous marginal zone lymphoma: a clinicopathological study of two cases illustrating the temporal progression of B. burgdorferi-associated B-cell proliferation in the skin. Histopathology 37(6), 501–508 (2000).
  • Monari P, Farisoglio C, Calzavara-Pinton PG. Borrelia burgdorferi-associated primary cutaneous marginal-zone B-cell lymphoma: a case report. Dermatology (Basel). 215(3), 229–232 (2007).
  • Wood GS, Kamath NV, Guitart J et al. Absence of Borrelia burgdorferi DNA in cutaneous B-cell lymphomas from the United States. J. Cutan. Pathol. 28(10), 502–507 (2001).
  • Li C, Inagaki H, Kuo TT, Hu S, Okabe M, Eimoto T. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 asian cases. Am. J. Surg. Pathol. 27(8), 1061–1069 (2003).
  • Slater DN. Borrelia burgdorferi-associated primary cutaneous B-cell lymphoma. Histopathology 38(1), 73–77 (2001).
  • Aberer E, Neumann R, Stanek G. Is localised scleroderma a Borrelia infection? Lancet 2(8449), 278 (1985).
  • Weide B, Walz T, Garbe C. Is morphoea caused by Borrelia burgdorferi? A review. Br. J. Dermatol. 142(4), 636–644 (2000).
  • Goodlad JR, Davidson MM, Gordon P, Billington R, Ho-Yen DO. Morphoea and Borrelia burgdorferi: results from the Scottish Highlands in the context of the world literature. MP, Mol. Pathol. 55(6), 374–378 (2002).
  • Büchner SA. [Morphea – a tick transmitted borreliosis of the skin? A contribution to the pathogenesis of circumscript scleroderma]. Z. Hautkr. 64(8), 661–664, 667 (1989).
  • Granter SR, Barnhill RL, Duray PH. Borrelial fasciitis: diffuse fasciitis and peripheral eosinophilia associated with Borrelia infection. Am. J. Dermatopathol. 18(5), 465–473 (1996).
  • Asbrink E, Hovmark A, Olsson I. Clinical manifestations of acrodermatitis chronica atrophicans in 50 Swedish patients. Zentralbl. Bakteriol. Mikrobiol. Hyg. A. 263(1–2), 253–261 (1986).
  • Duray PH, Asbrink E, Weber K. The cutaneous manifestations of human Lyme disease: a widening spectrum. Adv. Dermatol. 4, 255–275 (1989).
  • Hercogova J. Borrelia burgdorferi: a protagonist in Lyme disease, a bystander in morphoea? J. Eur. Acad. Dermatol. Venereol. 16(2), 98–99 (2002).
  • Aberer E, Klade H, Hobisch G. A clinical, histological, and immunohistochemical comparison of acrodermatitis chronica atrophicans and morphea. Am. J. Dermatopathol. 13(4), 334–341 (1991).
  • Büchner SA, Rufli T. [Morphaea profunda]. Hautarzt. 41(3), 155–157 (1990).
  • Abele DC, Bedingfield RB, Chandler FW, Given KS. Progressive facial hemiatrophy (Parry–Romberg syndrome) and borreliosis. J. Am. Acad. Dermatol. 22(3), 531–533 (1990).
  • Breier FH, Aberer E, Stanek G, Khanakaha G, Schlick A, Tappeiner G. Isolation of Borrelia afzelii from circumscribed scleroderma. Br. J. Dermatol. 140(5), 925–930 (1999).
  • Posey JE, Gherardini FC. Lack of a role for iron in the Lyme disease pathogen. Science 288(5471), 1651–1653 (2000).
  • Parveen N, Caimano M, Radolf JD, Leong JM. Adaptation of the Lyme disease spirochaete to the mammalian host environment results in enhanced glycosaminoglycan and host cell binding. Mol. Microbiol. 47(5), 1433–1444 (2003).
  • Fischer JR, LeBlanc KT, Leong JM. Fibronectin binding protein BBK32 of the Lyme disease spirochete promotes bacterial attachment to glycosaminoglycans. Infect. Immun. 74(1), 435–441 (2006).
  • Eisendle K, Grabner T, Zelger B. Morphoea: a manifestation of infection with Borrelia species? Br. J. Dermatol. 157(6), 1189–1198 (2007).
  • Behar SM, Porcelli SA. Mechanisms of autoimmune disease induction. The role of the immune response to microbial pathogens. Arthritis Rheum. 38(4), 458–476 (1995).
  • Prinz JC, Kutasi Z, Weisenseel P, Pótó L, Battyáni Z, Ruzicka T. ‘Borrelia-associated early-onset morphea’: a particular type of scleroderma in childhood and adolescence with high titer antinuclear antibodies? Results of a cohort analysis and presentation of three cases. J. Am. Acad. Dermatol. 60(2), 248–255 (2009).
  • Meffert JJ, Davis BM, Grimwood RE. Lichen sclerosus. J. Am. Acad. Dermatol. 32(3), 393–416; quiz 417 (1995).
  • Powell JJ, Wojnarowska F. Lichen sclerosus. Lancet 353(9166), 1777–1783 (1999).
  • Val I, Almeida G. An overview of lichen sclerosus. Clin. Obstet. Gynecol. 48(4), 808–817 (2005).
  • Marini A, Blecken S, Ruzicka T, Hengge UR. [Lichen sclerosus. New aspects of pathogenesis and treatment]. Hautarzt. 56(6), 550–555 (2005).
  • Shono S, Imura M, Ota M, Osaku A, Shinomiya S, Toda K. Lichen sclerosus et atrophicus, morphea, and coexistence of both diseases. Histological studies using lectins. Arch. Dermatol. 127(9), 1352–1356 (1991).
  • Peterson LS, Nelson AM, Su WP. Classification of morphea (localized scleroderma). Mayo Clin. Proc. 70(11), 1068–1076 (1995).
  • Aberer E, Schmidt BL, Breier F, Kinaciyan T, Luger A. Amplification of DNA of Borrelia burgdorferi in urine samples of patients with granuloma annulare and lichen sclerosus et atrophicus. Arch. Dermatol. 135(2), 210–212 (1999).
  • Aberer E, Stanek G. Histological evidence for spirochetal origin of morphea and lichen sclerosus et atrophicans. Am. J. Dermatopathol. 9(5), 374–379 (1987).
  • Breier F, Khanakah G, Stanek G et al. Isolation and polymerase chain reaction typing of Borrelia afzelii from a skin lesion in a seronegative patient with generalized ulcerating bullous lichen sclerosus et atrophicus. Br. J. Dermatol. 144(2), 387–392 (2001).
  • Shelley WB, Shelley ED, Grunenwald MA, Anders TJ, Ramnath A. Long-term antibiotic therapy for balanitis xerotica obliterans. J. Am. Acad. Dermatol. 40(1), 69–72 (1999).
  • Shelley WB, Shelley ED, Amurao CV. Treatment of lichen sclerosus with antibiotics. Int. J. Dermatol. 45(9), 1104–1106 (2006).
  • Fujiwara H, Fujiwara K, Hashimoto K et al. Detection of Borrelia burgdorferi DNA (B. garinii or B. afzelii) in morphea and lichen sclerosus et atrophicus tissues of German and Japanese but not of US patients. Arch. Dermatol. 133(1), 41–44 (1997).
  • Hulínská D, Barták P, Hercogová J, Hancil J, Basta J, Schramlová J. Electron microscopy of Langerhans cells and Borrelia burgdorferi in Lyme disease patients. Zentralbl. Bakteriol. 280(3), 348–359 (1994).
  • Alban PS, Johnson PW, Nelson DR. Serum-starvation-induced changes in protein synthesis and morphology of Borrelia burgdorferi. Microbiology (Reading, Engl.) 146 (Pt 1), 119–127 (2000).
  • Garon CF, Dorward DW, Corwin MD. Structural features of Borrelia burgdorferi – the Lyme disease spirochete: silver staining for nucleic acids. Scanning Microsc. Suppl. 3, 109–115 (1989).
  • Beermann C, Wunderli-Allenspach H, Groscurth P, Filgueira L. Lipoproteins from Borrelia burgdorferi applied in liposomes and presented by dendritic cells induce CD8(+) T-lymphocytes in vitro. Cell. Immunol. 201(2), 124–131 (2000).
  • Shoberg RJ, Thomas DD. Specific adherence of Borrelia burgdorferi extracellular vesicles to human endothelial cells in culture. Infect. Immun. 61(9), 3892–3900 (1993).
  • Dickie RJ, Horne CH, Sutherland HW, Bewsher PD, Stankler L. Direct evidence of localised immunological damage in vulvar lichen sclerosus et atrophicus. J. Clin. Pathol. 35(12), 1395–1397 (1982).
  • Benvenga S, Santarpia L, Trimarchi F, Guarneri F. Human thyroid autoantigens and proteins of Yersinia and Borrelia share amino acid sequence homology that includes binding motifs to HLA-DR molecules and T-cell receptor. Thyroid 16(3), 225–236 (2006).
  • Vaccaro M, Guarneri F, Borgia F, Cannavò SP, Benvenga S. Association of lichen sclerosus and autoimmune thyroiditis: possible role of Borrelia burgdorferi? Thyroid 12(12), 1147–1148 (2002).
  • Sapi E, MacDonald A. Biofilms of Borrelia burgdorferi in chronic cutaneous borreliosis. Am. J. Clin. Pathol. 129, 988–989 (2008).
  • Eisendle K, Mueller H, Zelger B. Biofilms of Borrelia burgdorferi in chronic cutaneous borreliosis. Am. J. Clin. Pathol. 129, 989–990 (2008).
  • Yamada M, Ikegami A, Kuramitsu HK. Synergistic biofilm formation by Treponema denticola and Porphyromonas gingivalis. FEMS Microbiol. Lett. 250(2), 271–277 (2005).
  • Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 115(5), 1272–1277 (1998).
  • Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 284(5418), 1318–1322 (1999).
  • Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 358(9276), 135–138 (2001).
  • Smoller BR, Madhusudhan KT, Scott MA, Horn TD. Granuloma annulare: another manifestation of Bartonella infection? Am. J. Dermatopathol. 23(6), 510–513 (2001).
  • Strle F, Preac-Mursic V, Ruzic E, Wilske B, Cimperman J. Isolation of Borrelia burgdorferi from a skin lesion in a patient with granuloma annulare. Infection 19(5), 351–352 (1991).
  • Svecova D, Buchvald J. [Borrelia burgdorferi antibodies in scleroderma circumscripta, lichen sclerosus et atrophicus, erythema nodosum, granuloma annulare, erythema annulare and chronic urticaria]. Bratisl. Lek. Listy 101(4), 194–199 (2000).
  • Sviberg P, Schroeder MT, Niiranen K, Nevanlinna A, Panelius J, Ranki A. The many faces of solitary and multiple erythema migrans. Acta Derm. Venereol. (In Press).
  • Duray PH. Clinical pathologic correlations of Lyme disease. Rev. Infect. Dis. 11(Suppl. 6), S1487–S1493 (1989).
  • Halkier-Sørensen L, Kragballe K, Hansen K. Antibodies to the Borrelia burgdorferi flagellum in patients with scleroderma, granuloma annulare and porphyria cutanea tarda. Acta Derm. Venereol. 69(2), 116–119 (1989).
  • Berger BW. Dermatologic manifestations of Lyme disease. Rev. Infect. Dis. 11(Suppl. 6), S1475–S1481 (1989).
  • Ziemer M, Grabner T, Eisendle K, Baltaci M, Zelger B. Granuloma annulare – a manifestation of infection with Borrelia? J. Cutan. Pathol. 35(11), 1050–1057 (2008).
  • Fernandez-Flores A, Ruzic-Sabljic E. Granuloma annulare displaying pseudorosettes in Borelia infection. Acta Dermatovenerol. Alp. Panonica. Adriat. 17(4), 171–176 (2008).
  • Gualco F, Zaccaria E, Drago F, Rebora A. Interstitial granuloma annulare and borreliosis: a new case. J. Eur. Acad. Dermatol. Venereol. 21(8), 1117–1118 (2007).
  • Moreno C, Kutzner H, Palmedo G, Goerttler E, Carrasco L, Requena L. Interstitial granulomatous dermatitis with histiocytic pseudorosettes: a new histopathologic pattern in cutaneous borreliosis. Detection of Borrelia burgdorferi DNA sequences by a highly sensitive PCR-ELISA. J. Am. Acad. Dermatol. 48(3), 376–384 (2003).
  • Xu Z, Ma D, Luo W, Zhu Y. Detection of Borrelia burgdorferi DNA in granulomatous tissues from patients with sarcoidosis using polymerase chain reaction in situ technique. Chin. Med. Sci. J. 11(4), 220–223 (1996).
  • Ishihara M, Ohno S, Ono H et al. Seroprevalence of anti-Borrelia antibodies among patients with confirmed sarcoidosis in a region of Japan where Lyme borreliosis is endemic. Graefes Arch. Clin. Exp. Ophthalmol. 236(4), 280–284 (1998).
  • Derler AM, Eisendle K, Baltaci M, Obermoser G, Zelger B. High prevalence of ‘Borrelia-like’ organisms in skin biopsies of sarcoidosis patients from western Austria. J. Cutan. Pathol. 36(12), 1262–1268 (2009).
  • Ishihara M, Ishida T, Isogai E et al. Detection of antibodies to Borrelia species among patients with confirmed sarcoidosis in a region where Lyme disease is nonendemic. Graefes Arch. Clin. Exp. Ophthalmol. 234(12), 770–773 (1996).
  • Klint H, Siboni AH. [Borreliosis associated with Lofgren’s syndrome]. Ugeskr. Laeg. 162(31), 4154–4155 (2000).
  • Spiegel IB, White SD, Foley JE, Drazenovich NL, Ihrke PJ, Affolter VK. A retrospective study of cutaneous equine sarcoidosis and its potential infectious aetiological agents. Vet. Dermatol. 17(1), 51–62 (2006).
  • Montemurro L, Rizzato G. Is sarcoidosis a borreliosis? Sarcoidosis 8(2), 134–135 (1991).
  • Liu HG. [Spirochetes in the cheilits granulomatosa and sarcoidosis]. Zhonghua Yi Xue Za Zhi 73(3), 142–4, 189 (1993).
  • Arcangeli G, Calabro S, Cisno F, Zambotto FM, Drigo R, Ferraresso A. Determination of antibodies to Borrelia burgdorferi in sarcoidosis. Sarcoidosis 11(1), 32–33 (1994).
  • Hua B, Li QD, Wang FM, Ai CX, Luo WC. Borrelia burgdorferi infection may be the cause of sarcoidosis. Chin. Med. J. 105(7), 560–563 (1992).
  • Chen YQ, Miao JZ, Zhang XZ. [Determination of antibody of Borrelia burgdorferi in the serum of patients with sarcoidosis and its significance]. Zhonghua Nei Ke Za Zhi 33(1), 15–17 (1994).
  • Morris JT, Longfield RN. Sarcoidosis and ELISA for Borrelia burgdorferi. South. Med. J. 87(6), 590–591 (1994).
  • Lian W, Luo W. Borrelia burgdorferi DNA in biological samples from patients with sarcoidosis using the polymerase chain reaction technique. Chin. Med. Sci. J. 10(2), 93–95 (1995).
  • Eisendle K, Baltaci M, Kutzner H, Zelger B. Detection of spirochaetal microorganisms by focus floating microscopy in necrobiosis lipoidica in patients from central Europe. Histopathology 52(7), 877–884 (2008).
  • Zelger B, Eisendle K, Mensing C, Zelger B. Detection of spirochetal micro-organisms by focus-floating microscopy in necrobiotic xanthogranuloma. J. Am. Acad. Dermatol. 57(6), 1026–1030 (2007).
  • Tothova SM, Bonin S, Trevisan G, Stanta G. Mycosis fungoides: is it a Borrelia burgdorferi-associated disease? Br. J. Cancer 94(6), 879–883 (2006).
  • Ziemer M, Eisendle K, Müller H, Zelger B. Lymphocytic infiltration of the skin (Jessner–Kanof) but not reticular erythematous mucinosis occasionally represents clinical manifestations of Borrelia-associated pseudolymphoma. Br. J. Dermatol. 161(3), 583–590 (2009).
  • Kaatz M, Zelger B, Norgauer J, Ziemer M. Lymphocytic infiltration (Jessner–Kanof): lupus erythematosus tumidus or a manifestation of borreliosis? Br. J. Dermatol. 157(2), 403–405 (2007).
  • Abele DC, Anders KH, Chandler FW. Benign lymphocytic infiltration (Jessner–Kanof): another manifestation of borreliosis? J. Am. Acad. Dermatol. 21(4 Pt 1), 795–797 (1989).
  • Bagot M, Revuz J. Jessner–Kanof lesion and Borrelia infection. J. Am. Acad. Dermatol. 23(4 Pt 1), 772–773 (1990).
  • Abele DC, Anders KH. The many faces and phases of borreliosis II. J. Am. Acad. Dermatol. 23(3 Pt 1), 401–410 (1990).
  • Ziemer M, Eisendle K, Zelger B. New concepts on erythema annulare centrifugum: a clinical reaction pattern that does not represent a specific clinicopathological entity. Br. J. Dermatol. 160(1), 119–126 (2009).
  • Aberer E. Lyme borreliosis – an update. J. Dtsch. Dermatol. Ges. 5(5), 406–414 (2007).
  • Weger W, Müllegger RR. Histopathology and immunohistochemistry of dermatoborrelioses. Acta. Dermatoven. APA 10, 135–142 (2011).
  • Grant-Kels J. Nodular and diffuse dermatitis. In: Color Atlas of Dermopathology. Informa Healthcare, NY, USA, 98 (2007)
  • Berger BW, Johnson RC, Kodner C, Coleman L. Cultivation of Borrelia burgdorferi from erythema migrans lesions and perilesional skin. J. Clin. Microbiol. 30(2), 359–361 (1992).
  • van Dam AP, Kuiper H, Vos K et al. Different genospecies of Borrelia burgdorferi are associated with distinct clinical manifestations of Lyme borreliosis. Clin. Infect. Dis. 17(4), 708–717 (1993).
  • Wormser GP, Bittker S, Cooper D, Nowakowski J, Nadelman RB, Pavia C. Comparison of the yields of blood cultures using serum or plasma from patients with early Lyme disease. J. Clin. Microbiol. 38(4), 1648–1650 (2000).
  • Pachner AR, Zhang WF, Schaefer H, Schaefer S, O’Neill T. Detection of active infection in nonhuman primates with Lyme neuroborreliosis: comparison of PCR, culture, and a bioassay. J. Clin. Microbiol. 36(11), 3243–3247 (1998).
  • Picken MM, Picken RN, Han D et al. A two year prospective study to compare culture and polymerase chain reaction amplification for the detection and diagnosis of Lyme borreliosis. MP, Mol. Pathol. 50(4), 186–193 (1997).
  • Lazarus JJ, McCarter AL, Neifer-Sadhwani K, Wooten RM. ELISA-based measurement of antibody responses and PCR-based detection profiles can distinguish between active infection and early clearance of Borrelia burgdorferi. Clin. Dev. Immunol. 138069, doi: 10.1155/2012/138069 (2012).
  • Steere AC, McHugh G, Damle N, Sikand VK. Prospective study of serologic tests for Lyme disease. Clin. Infect. Dis. 47(2), 188–195 (2008).
  • Bhate C, Schwartz RA. Lyme disease: Part II. Management and prevention. J. Am. Acad. Dermatol. 64(4), 639–653; quiz 654, 653 (2011).
  • CDC. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb. Mortal. Wkly Rep. 44(31), 590–591 (1995).
  • Brouqui P, Bacellar F, Baranton G et al.; ESCMID Study Group on Coxiella, Anaplasma, Rickettsia and Bartonella; European Network for Surveillance of Tick-Borne Diseases. Guidelines for the diagnosis of tick-borne bacterial diseases in Europe. Clin. Microbiol. Infect. 10(12), 1108–1132 (2004).
  • Dressler F, Whalen JA, Reinhardt BN, Steere AC. Western blotting in the serodiagnosis of Lyme disease. J. Infect. Dis. 167(2), 392–400 (1993).
  • Branda JA, Aguero-Rosenfeld ME, Ferraro MJ, Johnson BJ, Wormser GP, Steere AC. 2-tiered antibody testing for early and late Lyme disease using only an immunoglobulin G blot with the addition of a VlsE band as the second-tier test. Clin. Infect. Dis. 50(1), 20–26 (2010).
  • Craven RB, Quan TJ, Bailey RE et al. Improved serodiagnostic testing for Lyme disease: results of a multicenter serologic evaluation. Emerging Infect. Dis. 2(2), 136–140 (1996).
  • Brown SL, Hansen SL, Langone JJ. Role of serology in the diagnosis of Lyme disease. JAMA 282(1), 62–66 (1999).
  • Wormser GP, Liveris D, Hanincová K et al. Effect of Borrelia burgdorferi genotype on the sensitivity of C6 and 2-tier testing in North American patients with culture-confirmed Lyme disease. Clin. Infect. Dis. 47(7), 910–914 (2008).
  • Binnicker MJ, Jespersen DJ, Harring JA, Rollins LO, Bryant SC, Beito EM. Evaluation of two commercial systems for automated processing, reading, and interpretation of Lyme borreliosis Western blots. J. Clin. Microbiol. 46(7), 2216–2221 (2008).
  • Craft JE, Fischer DK, Shimamoto GT, Steere AC. Antigens of Borrelia burgdorferi recognized during Lyme disease. Appearance of a new immunoglobulin M response and expansion of the immunoglobulin G response late in the illness. J. Clin. Invest. 78(4), 934–939 (1986).
  • Weinstein A. Editorial commentary: laboratory testing for Lyme disease: time for a change? Clin. Infect. Dis. 47(2), 196–197 (2008).
  • Nocton JJ, Dressler F, Rutledge BJ, Rys PN, Persing DH, Steere AC. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in synovial fluid from patients with Lyme arthritis. N. Engl. J. Med. 330(4), 229–234 (1994).
  • Lebech AM, Hansen K. Detection of Borrelia burgdorferi DNA in urine samples and cerebrospinal fluid samples from patients with early and late Lyme neuroborreliosis by polymerase chain reaction. J. Clin. Microbiol. 30(7), 1646–1653 (1992).
  • Liebling MR, Nishio MJ, Rodriguez A, Sigal LH, Jin T, Louie JS. The polymerase chain reaction for the detection of Borrelia burgdorferi in human body fluids. Arthritis Rheum. 36(5), 665–675 (1993).
  • Aguero-Rosenfeld ME, Wang G, Schwartz I, Wormser GP. Diagnosis of Lyme borreliosis. Clin. Microbiol. Rev. 18(3), 484–509 (2005).
  • Schmidt BL. PCR in laboratory diagnosis of human Borrelia burgdorferi infections. Clin. Microbiol. Rev. 10(1), 185–201 (1997).
  • Schwartz I, Wormser GP, Schwartz JJ et al. Diagnosis of early Lyme disease by polymerase chain reaction amplification and culture of skin biopsies from erythema migrans lesions. J. Clin. Microbiol. 30(12), 3082–3088 (1992).
  • Nocton JJ, Bloom BJ, Rutledge BJ et al. Detection of Borrelia burgdorferi DNA by polymerase chain reaction in cerebrospinal fluid in Lyme neuroborreliosis. J. Infect. Dis. 174(3), 623–627 (1996).
  • Sigal LH. The polymerase chain reaction assay for Borrelia burgdorferi in the diagnosis of Lyme disease. Ann. Intern. Med. 120(6), 520–521 (1994).
  • Berger BW, Clemmensen OJ, Ackerman AB. Lyme disease is a spirochetosis. A review of the disease and evidence for its cause. Am. J. Dermatopathol. 5(2), 111–124 (1983).
  • Eisendle K, Grabner T, Zelger B. Focus floating microscopy: ‘gold standard’ for cutaneous borreliosis? Am. J. Clin. Pathol. 127(2), 213–222 (2007).
  • Dattwyler RJ, Volkman DJ, Conaty SM, Platkin SP, Luft BJ. Amoxycillin plus probenecid versus doxycycline for treatment of erythema migrans borreliosis. Lancet 336(8728), 1404–1406 (1990).
  • Luger SW, Paparone P, Wormser GP et al. Comparison of cefuroxime axetil and doxycycline in treatment of patients with early Lyme disease associated with erythema migrans. Antimicrob. Agents Chemother. 39(3), 661–667 (1995).
  • Nadelman RB, Luger SW, Frank E, Wisniewski M, Collins JJ, Wormser GP. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann. Intern. Med. 117(4), 273–280 (1992).
  • Luft BJ, Dattwyler RJ, Johnson RC et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann. Intern. Med. 124(9), 785–791 (1996).
  • Dattwyler RJ, Luft BJ, Kunkel MJ et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. N. Engl. J. Med. 337(5), 289–294 (1997).
  • Massarotti EM, Luger SW, Rahn DW et al. Treatment of early Lyme disease. Am. J. Med. 92(4), 396–403 (1992).
  • Steere AC, Hutchinson GJ, Rahn DW et al. Treatment of the early manifestations of Lyme disease. Ann. Intern. Med. 99(1), 22–26 (1983).
  • Nowakowski J, McKenna D, Nadelman RB et al. Failure of treatment with cephalexin for Lyme disease. Arch. Fam. Med. 9(6), 563–567 (2000).
  • Agger WA, Callister SM, Jobe DA. In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone. Antimicrob. Agents Chemother. 36(8), 1788–1790 (1992).
  • Wormser GP, Ramanathan R, Nowakowski J et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 138(9), 697–704 (2003).
  • Kowalski TJ, Tata S, Berth W, Mathiason MA, Agger WA. Antibiotic treatment duration and long-term outcomes of patients with early Lyme disease from a Lyme disease-hyperendemic area. Clin. Infect. Dis. 50(4), 512–520 (2010).
  • Klempner MS, Hu LT, Evans J et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N. Engl. J. Med. 345(2), 85–92 (2001).
  • Karlsson M, Hammers-Berggren S, Lindquist L, Stiernstedt G, Svenungsson B. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis. Neurology 44(7), 1203–1207 (1994).
  • Pfister HW, Preac-Mursic V, Wilske B, Schielke E, Sörgel F, Einhäupl KM. Randomized comparison of ceftriaxone and cefotaxime in Lyme neuroborreliosis. J. Infect. Dis. 163(2), 311–318 (1991).
  • Dattwyler RJ, Wormser GP, Rush TJ et al. A comparison of two treatment regimens of ceftriaxone in late Lyme disease. Wien. Klin. Wochenschr. 117(11–12), 393–397 (2005).
  • Dattwyler RJ, Halperin JJ, Volkman DJ, Luft BJ. Treatment of late Lyme borreliosis – randomised comparison of ceftriaxone and penicillin. Lancet 1(8596), 1191–1194 (1988).
  • Pfister HW, Preac-Mursic V, Wilske B, Einhäupl KM. Cefotaxime vs penicillin G for acute neurologic manifestations in Lyme borreliosis. A prospective randomized study. Arch. Neurol. 46(11), 1190–1194 (1989).
  • Dotevall L, Hagberg L. Successful oral doxycycline treatment of Lyme disease-associated facial palsy and meningitis. Clin. Infect. Dis. 28(3), 569–574 (1999).
  • Clark JR, Carlson RD, Sasaki CT, Pachner AR, Steere AC. Facial paralysis in Lyme disease. Laryngoscope 95(11), 1341–1345 (1985).
  • Wormser GP, Dattwyler RJ, Shapiro ED et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin. Infect. Dis. 43(9), 1089–1134 (2006).
  • Auwaerter PG. Point: antibiotic therapy is not the answer for patients with persisting symptoms attributable to Lyme disease. Clin. Infect. Dis. 45(2), 143–148 (2007).
  • Stricker RB. Counterpoint: long-term antibiotic therapy improves persistent symptoms associated with Lyme disease. Clin. Infect. Dis. 45(2), 149–157 (2007).
  • Mayer L, Merz S. An appraisal of ‘chronic Lyme disease’. N. Engl. J. Med. 358(4), 428 (2008).
  • Klempner MS. Controlled trials of antibiotic treatment in patients with post-treatment chronic Lyme disease. Vector Borne Zoonotic Dis. 2(4), 255–263 (2002).
  • Embers ME, Barthold SW, Borda JT et al. Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection. PLoS ONE 7(1), e29914 (2012).
  • Yrjänäinen H, Hytönen J, Hartiala P, Oksi J, Viljanen MK. Persistence of borrelial DNA in the joints of Borrelia burgdorferi-infected mice after ceftriaxone treatment. APMIS 118(9), 665–673 (2010).
  • Hodzic E, Feng S, Holden K, Freet KJ, Barthold SW. Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrob. Agents Chemother. 52(5), 1728–1736 (2008).
  • Ma Y, Sturrock A, Weis JJ. Intracellular localization of Borrelia burgdorferi within human endothelial cells. Infect. Immun. 59(2), 671–678 (1991).
  • Klempner MS, Noring R, Rogers RA. Invasion of human skin fibroblasts by the Lyme disease spirochete, Borrelia burgdorferi. J. Infect. Dis. 167(5), 1074–1081 (1993).
  • Girschick HJ, Huppertz HI, Rüssmann H, Krenn V, Karch H. Intracellular persistence of Borrelia burgdorferi in human synovial cells. Rheumatol. Int. 16(3), 125–132 (1996).
  • LivengoodJA, GilmoreRD Jr. Invasion of human neuronal and glial cells by an infectious strain of Borrelia burgdorferi. Microbes Infect. 8(14–15), 2832–2840 (2006).
  • Montgomery RR, Lusitani D, de Boisfleury Chevance A, Malawista SE. Human phagocytic cells in the early innate immune response to Borrelia burgdorferi. J. Infect. Dis. 185(12), 1773–1779 (2002).
  • Wormser GP, Baker PJ, O’Connell S, Pachner AR, Schwartz I, Shapiro ED. Critical analysis of treatment trials of rhesus macaques infected with Borrelia burgdorferi reveals important flaws in experimental design. Vector Borne Zoonotic Dis. 12(7), 535–538 (2012).
  • Aberer E, Stanek G, Ertl M, Neumann R. Evidence for spirochetal origin of circumscribed scleroderma (morphea). Acta Derm. Venereol. 67(3), 225–231 (1987).
  • Weber K, Preac-Mursic V, Reimers CD. Spirochetes isolated from two patients with morphea. Infection 16(1), 25–26 (1988).
  • Aberer E, Kollegger H, Kristoferitsch W, Stanek G. Neuroborreliosis in morphea and lichen sclerosus et atrophicus. J. Am. Acad. Dermatol. 19(5 Pt 1), 820–825 (1988).
  • Ross SA, Sánchez JL, Taboas JO. Spirochetal forms in the dermal lesions of morphea and lichen sclerosus et atrophicus. Am. J. Dermatopathol. 12(4), 357–362 (1990).
  • Aberer E, Klade H, Stanek G, Gebhart W. Borrelia burgdorferi and different types of morphea. Dermatologica 182(3), 145–154 (1991).
  • Schempp C, Bocklage H, Lange R, Kölmel HW, Orfanos CE, Gollnick H. Further evidence for Borrelia burgdorferi infection in morphea and lichen sclerosus et atrophicus confirmed by DNA amplification. J. Invest. Dermatol. 100(5), 717–720 (1993).
  • Schempp C, Bocklage H, Owsianowski M, Lange R, Orfanos CE, Gollnick H. [In vivo and in vitro detection of Borrelia infection in morphea-like skin changes with negative Borrelia serology]. Hautarzt. 44(1), 14–18 (1993).
  • Weidenthaler B, Roux M, Moter SE, Schulze HJ, Kramer MD. [Sclerodermiform skin changes in Borrelia burgdorferi infection. Diagnostic use of polymerase chain reaction]. Hautarzt. 45(3), 171–175 (1994).
  • Granter SR, Barnhill RL, Hewins ME, Duray PH. Identification of Borrelia burgdorferi in diffuse fasciitis with peripheral eosinophilia: borrelial fasciitis. JAMA 272(16), 1283–1285 (1994).
  • Ranki A, Aavik E, Peterson P, Schauman K, Nurmilaakso P. Successful amplification of DNA specific for Finnish Borrelia burgdorferi isolates in erythema chronicum migrans but not in circumscribed scleroderma lesions. J. Invest. Dermatol. 102(3), 339–345 (1994).
  • Dillon WI, Saed GM, Fivenson DP. Borrelia burgdorferi DNA is undetectable by polymerase chain reaction in skin lesions of morphea, scleroderma, or lichen sclerosus et atrophicus of patients from North America. J. Am. Acad. Dermatol. 33(4), 617–620 (1995).
  • De Vito JR, Merogi AJ, Vo T et al. Role of Borrelia burgdorferi in the pathogenesis of morphea/scleroderma and lichen sclerosus et atrophicus: a PCR study of thirty-five cases. J. Cutan. Pathol. 23(4), 350–358 (1996).
  • Trevisan G, Stinco G, Nobile C. Detection of Borrelia burgdorferi in skin biopsies from patients with morphea by polymerase chainreaction. J. Eur. Acad. Dermatol. Venereol. 6, 15–19 (1996).
  • Colomé-Grimmer MI, Payne DA, Tyring SK, Sánchez RL. Borrelia burgdorferi DNA and Borrelia hermsii DNA are not associated with morphea or lichen sclerosus et atrophicus in the southwestern United States. Arch. Dermatol. 133(9), 1174 (1997).
  • Alonso-Llamazares J, Persing DH, Anda P, Gibson LE, Rutledge BJ, Iglesias L. No evidence for Borrelia burgdorferi infection in lesions of morphea and lichen sclerosus et atrophicus in Spain. A prospective study and literature review. Acta Derm. Venereol. 77(4), 299–304 (1997).
  • Ozkan S, Atabey N, Fetil E, Erkizan V, Günes AT. Evidence for Borrelia burgdorferi in morphea and lichen sclerosus. Int. J. Dermatol. 39(4), 278–283 (2000).
  • Eisendle K, Grabner T, Kutzner H, Zelger B. Lichen sclerosus et atrophicus: a manifestation of infection with Borrelia species? Arch. Dermatol. 144(5), 591–598 (2008).
  • Zollinger T, Mertz KD, Schmid M, Schmitt A, Pfaltz M, Kempf W. Borrelia in granuloma annulare, morphea and lichen sclerosus: a PCR-based study and review of the literature. J. Cutan. Pathol. 37(5), 571–577 (2010).
  • Santos M, Ribeiro-Rodrigues R, Talhari C, Ferreira LC, Zelger B, Talhari S. Presence of Borrelia burgdorferi ‘Sensu Lato’ in patients with morphea from the Amazonic region in Brazil. Int. J. Dermatol. 50(11), 1373–1378 (2011).
  • Herxheimer K, Hartmann K. Über Acrodermatitis chronica atrophicans. Arch. Dermatol. Syphilol. 164, 349–356 (1931).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.